Table 2.
Baseline characteristics in the high-EDSS subgroups
| PRISMS (N = 59) | PRISMS/SPECTRIMS | |||||
|---|---|---|---|---|---|---|
| All patients (n = 335) | With baseline disease activitya (n = 195) |
|||||
| Characteristic | Placebo (n = 28) | sc IFN β-1a 44 μg tiw (n = 31) | Placebo (n = 164) | sc IFN β-1a 44 μg tiw (n = 171) | Placebo (n = 92) | sc IFN β-1a 44 μg tiw (n = 103) |
| Age, years | ||||||
| Mean (SD) | 37.6 (8.0) | 36.6 (7.6) | 41.5 (7.3) | 41.2 (7.3) | 40.0 (7.4) | 39.4 (7.2) |
| Female sex, n (%) | 24 (86) | 17 (55) | 108 (65.9) | 107 (62.6) | 62 (67.4) | 66 (64.1) |
| Time since diagnosis, yearsb | ||||||
| Mean (SD) | 8.9 (6.4) | 9.2 (6.4) | 13.3 (7.3) | 12.4 (7.0) | 12.0 (7.5) | 10.8 (6.4) |
| EDSS score at baselineb | ||||||
| Mean (SD) | 4.4 (0.5) | 4.5 (0.6) | 5.2 (0.8) | 5.2 (0.8) | 5.1 (0.8) | 5.0 (0.8) |
| Relapses in previous 2 yearsb | ||||||
| Mean (SD) | 3.2 (1.4) | 2.8 (1.1) | 1.3 (1.5)c | 1.3 (1.5)d | 2.2 (1.4) | 2.1 (1.4) |
| Burden of disease,b mm2 | ||||||
| Mean (SD) | 4124.7 (3973.1) | 4110.2 (3324.8) | 4459.6 (3775.5) | 4441.6 (4213.7) | 4601.8 (4082.3) | 4879.7 (4608.9) |
EDSS Expanded Disability Status Scale, IFN β-1a interferon beta-1a, sc subcutaneous, SD standard deviation, tiw three times weekly
aActive disease defined as having ≥ 1 relapse within 2 years before baseline or ≥ 1 gadolinium-enhancing lesion at baseline
bEquals the number of patients with available data
cn = 163
dn = 170